Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study

被引：0

作者：

Dhodapkar, Madhav ^{[1
]}

Bumma, Naresh ^{[2
]}

Richter, Joshua ^{[3
]}

Lee, Hans ^{[4
]}

Hoffman, James ^{[5
]}

Suvannasankha, Attaya ^{[6
,7
]}

Lentzsch, Suzanne ^{[8
]}

Shah, Mansi ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Wu, Ka Lung ^{[12
]}

Pianko, Matthew ^{[13
]}

Silbermann, Rebecca ^{[14
]}

Min, Chang-Ki ^{[15
]}

Vekemans, Marie-Christiane Madeleine ^{[16
]}

Munder, Markus ^{[17
]}

Byun, Ja Min ^{[18
]}

Martinez Lopez, Joaquin ^{[19
]}

DeVeaux, Michelle ^{[20
]}

Lorenc, Karen Rodriguez ^{[20
]}

Kroog, Glenn ^{[20
]}

Houvras, Yariv ^{[20
]}

Jagannath, Sundar ^{[1
,21
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[5] Univ Miami Hlth Syst, Miami, FL USA

[6] Univ Indianapolis, Simon Canc Ctr, Indianapolis, IN USA

[7] Roudebush VAMC, Indianapolis, IN USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[13] Univ Michigan, Rogel Canc Ctr, Sch Med, Ann Arbor, MI USA

[14] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[15] Seoul St Marys Hosp, Seoul, South Korea

[16] Univ Catholique Louvain UCLouvain, Dept Internal Med, Brussels, Belgium

[17] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[18] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[19] Univ Complutense, Hosp Univ 12 octubre, CNIO, Madrid, Spain

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-247

引用

页码：S172 / S172

页数：1

共 50 条

[21] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Xiaohui Gao
Hui Zeng
Xiaoyan Zhao
Haibing Wu
Minchao Yan
Yuan Li
Gang Zhang
Fei Sun
BMC Cancer, 23
[22] EFFICACY AND SAFETY OF SELINEXOR FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS
Abushanab, D.
Mraiche, F.
Al-Badriyeh, D.
VALUE IN HEALTH, 2021, 24 : S22 - S22
[23] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Shafei, Laila
Bashir, Shaima
Chan, Esther W.
Abushanab, Dina
Hamad, Anas
Al-Badriyeh, Daoud
CURRENT PROBLEMS IN CANCER, 2024, 50
[24] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Gao, Xiaohui
Zeng, Hui
Zhao, Xiaoyan
Wu, Haibing
Yan, Minchao
Li, Yuan
Zhang, Gang
Sun, Fei
BMC CANCER, 2023, 23 (01)
[25] Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients
Mangiacavalli, Silvia
Pica, GianMatteo
Varettoni, Marzia
Lazzarino, Mario
Corso, Alessandro
EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (03) : 240 - 241
[26] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
Mellqvist, U. H.
Paba-Prada, C.
Palumbo, A.
Plesner, T.
Sonneveld, P.
Voorhees, P.
Byrne, C.
Harmenberg, J.
Nordstrom, E.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 375 - 376
[27] Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis
Zhou, Dao-Bin
Yu, Li
Du, Xin
Jin, Jie
Cai, Zhen
Chen, Fangping
Li, Xiao
Wu, Depei
Meng, Fanyi
Ai, Huisheng
Zhang, Jingshan
Wortman-Vayn, Honeylet
Mei, Jay
Wang, Jianmin
Hou, Jian
BLOOD, 2013, 122 (21)
[28] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
Mateos, Maria-Victoria
Blade, Joan
Larocca, Alessandra
Oriol, Albert
Rodriguez, Paula
Alegre, Adrian
Cavo, Michele
Moreb, Jan S.
Paner, Agne
Gabrail, Nashat
Halka, Kathleen G.
Hassoun, Hani
Maisel, Christopher
Mazumder, Amitabha
Zonder, Jeffrey A.
Ocio, Enrique M.
Byrne, Catriona
Harmenberg, Johan
Thuresson, Sara
Nordstrom, Eva
Lindberg, Jakob
Richardson, Paul G.
BLOOD, 2017, 130
[29] European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide
Di Raimondo, Francesco
Kyriakou, Charalampia
Schmidt-Hieber, Martin
Vekemans, Marie-Christiane
Payer, Angel Ramirez
Bentsen, Pal Tore
Lauri, Birgitta
Kueenburg, Elisabeth
Lersch, Frederik
Rosettani, Barbara
Bacon, Pamela
Plesner, Torben
BLOOD, 2016, 128 (22)
[30] Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Richter, Joshua
Jagannath, Sundar
Lee, Hans
Hoffman, James E.
Zonder, Jeffrey
Zhou, Zheng-Yi
Garcia-Horton, Viviana
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Wenxin
Ma, Qiufei
Inocencio, Timothy
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Houvras, Yariv
Bumma, Naresh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S274 - S275

← 1 2 3 4 5 →